Pharma/Fine Chemicals Roundup – June 21

Dr. Reddy’s API Site in Mexico Receives U.S. FDA Warning

Pharmaceutical company Dr. Reddy’s Laboratories (Hyderabad, India) says that Industrias Quimicas Falcon de Mexico, its wholly owned manufacturing facility at Cuernavaca, Mexico has received a warning letter from the U.S. Food and Drug Administration (FDA). The facility produces intermediates and active pharmaceutical ingredients (API).

http://www.chemweek.com/markets/fine_chemicals_biotech/pharmaceutical_ingredients/35576.html


Evonik Completes Glycine Expansion in China

Evonik Industries says it has increased production capacity for the pharmaceutical amino acid glycine by 50% at the company's facility at Nanning, China, citing growth in demand. The expansion was achieved through efficiency gains in the plant's production process.

http://www.chemweek.com/home/top_of_the_news/35600.html


Grindeks Opens API Plant in Latvia

Pharmaceutical company Grindeks (Riga, Latvia) says it has opened an active pharmaceutical ingredients (API) manufacturing unit at Riga. Construction of the plant began in 2009 following a cooperation agreement on regular ursodeoxycholic acid (UDCA) supply was signed with Marenis Pharma (Bingen am Rhein, Germany).

http://www.chemweek.com/markets/fine_chemicals_biotech/pharmaceutical_ingredients/Grindeks-Opens-API-Plant-in-Latvia_35633.html


Tianyin Pharmaceutical Signs API Sales Deal with Bangladeshi Firm

Tianyin Pharmaceutical (Chengdu, China), a company that specializes in patented biopharmaceutical medicine, traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) says it has signed a sales and marketing agreement with Relations International (Dhaka), a company that specializes in the sales of API for Tianyin’s azithromycin API product sales in Bangladesh.

http://www.chemweek.com/markets/fine_chemicals_biotech/pharmaceutical_ingredients/Tianyin-Pharmaceutical-Signs-API-Sales-Deal-with-Bangladeshi-Firm_35640.html